Suneva Medical closed $25 million financing to support continued growth opportunities, the company reports.

This financing, which includes $25 million equity investment from Essex Woodlands, strengthens Suneva Medical's rapid revenue growth and further supports the ongoing commercialization of Bellafill® and Regenica®.

In conjunction with the investment, Essex Woodlands will receive one seat on Suneva Medical's board of directors and an independent seat will also be appointed. In addition to Essex Woodlands, other major equity shareholders include HealthCare Royalty Partners, Almirall, S.A. and Polaris Partners, the company reports. Leerink Partners LLC acted as the exclusive placement agent to the company for the offering.